This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides funding to Cayman Chemical Co Inc. to develop novel small molecule pharmacotherapies that can stimulate alveolar bone regeneration for dental applications. The $306,868 grant, awarded on April 8, 2025, with a completion date of April 7, 2026, aims to create EZH2 inhibitor compounds that can induce osteogenesis and address the clinical need for restoring alveolar bone lost due to periodontal disease. The company will utilize an AI-driven medicinal chemistry approach to design, synthesize, and test these novel bone-stimulating compounds, evaluating their potency, physiochemical properties, and metabolic stability. The most promising compounds will then be further optimized and tested in animal models of alveolar bone restoration under both normal and inflammatory conditions associated with periodontitis.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $306.9k | 4/8/25 |